FIELD: pharmaceutical industry.
SUBSTANCE: group of inventions relates to the therapeutically applicable high-dose anhydrous solutions of curcuminoids. A method of preparing a solution of curcuminoid suitable for administration comprising the following: adding an alkaline compound to glycerol in an amount of 2 mg to 20 mg of the alkaline compound per milliliter of glycerol, where the alkaline compound is selected from the group consisting of sodium carbonate, calcium carbonate and calcium hydroxide, and dissolving the curcuminoid in amounts of 20 to 250 mg of curcuminoid per milliliter of glycerol. A solution of curcuminoid suitable for administration, containing: an alkaline compound in glycerol in an amount of 2 mg to 20 mg of an alkaline compound per milliliter of glycerol, wherein the alkaline compound is selected from the group consisting of sodium carbonate, calcium carbonate and calcium hydroxide, and a curcuminoid in an amount of 200 milligrams curcuminoid per milliliter of glycerol.
EFFECT: administerable curcuminoid solution prepared by the above method is a stable high dose curcumin solution.
17 cl, 1 dwg, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
CURCUMIN-PEPTIDE CONJUGATES AND THEIR COMPOSITIONS | 2015 |
|
RU2744573C2 |
COMPOSITION OF SUBCUTANEOUS INJECTION FOR REDUCING BODY WEIGHT AND ITS APPLICATIONS | 2017 |
|
RU2753507C2 |
WATER-SOLUBLE COMPOSITION BASED ON CURCUMIN | 2023 |
|
RU2816692C1 |
METHOD FOR IMPROVING THERAPEUTIC EFFICACY OF CURCUMINOIDS AND ANALOGUES THEREOF | 2008 |
|
RU2491084C2 |
NEW LOW-POLARITY GUM RESIN EXTRACT OF BOSWELLIA AND ITS SYNERGETIC COMPOSITIONS | 2010 |
|
RU2578025C2 |
HERBAL COMPOSITIONS FOR TREATING ORAL DISEASES | 2007 |
|
RU2450819C2 |
PHARMACEUTICAL COMPOSITION POSSESSING ANTI-INFLAMMATORY PROPERTIES | 2010 |
|
RU2532384C2 |
METHOD OF OBTAINING CRYSTALLINE WATER-SOLUBLE NONHYGROSCOPIC ETHYLENEDIAMINE MONOETHANOLAMINE OR DIETHANOLAMINO SALT OF H-(2-PYRIDYL)-2-METHYL-4-OXY-2H-1,2-BENZTHIAZINE-3-CARBOXAMIDE-1,1-DIOXIDE | 0 |
|
SU1122225A3 |
AQUEOUS COMPOSITION CONTAINING DANTROLENE | 2016 |
|
RU2729043C2 |
ORAL COMPOSITION CONTAINING 3-{5-[4-(CYCLOPENTLOXY)-2-HYDROXYBENZOYL]-2-[(3-HYDROXY-1,2-BENZISOXAZOL-6-YL)METHOXY]PHENYL}PROPIONIC ACID OR ITS SALT | 2007 |
|
RU2436576C2 |
Authors
Dates
2023-11-28—Published
2020-02-05—Filed